<DOC>
	<DOCNO>NCT00094016</DOCNO>
	<brief_summary>The primary objective study compare QVAR-Easi-Breathe 100 mcg/day QVAR-Easi-Breathe 200 mcg/day placebo relative change force expiratory volume 1 second ( FEV1 ) result follow 12 week treatment . Secondary objective daily asthma symptom score ( per week ) , morning peak expiratory flow ( PEF ) value , nocturnal awaken utilization rescue medication per day also evaluate . In addition , exploratory evaluation assess comparability two device ( i.e. , QVAR-Easi-Breathe versus QVAR-MDI ) dose level .</brief_summary>
	<brief_title>Evaluation Two Doses QVAR Breath Operated Metered Dose Inhalers Asthmatic Children</brief_title>
	<detailed_description />
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Male female child age 5 11 year screen visit Documented clinical evidence asthma ( FEV1 = 6590 % ) Ability perform acceptable reproducible spirometry per ATS guideline Ability perform PEF determination Reversible bronchoconstriction verify &gt; 12 % increase FEV1 Otherwise healthy child clinicallyacceptable medical history , physical examination , vital sign clinical laboratory parameter within acceptable range asthma patient The parent guardian must willing give write informed consent well patient assent able adhere dose visit schedule . Patients use inhaled corticosteroid within 30 day prior screen visit . Allergy sensitivity beclomethasone dipropionate ( BDP ) component formulation use CTM Patients demonstrate increase decrease FEV1 &gt; 20 % screen baseline visit . Patients unable use meter dose inhaler ( MDI ) without spacer device . Patients require use &gt; 12 puff per day albuterol 3 consecutive day screen baseline visit . Patients evidence growth retardation Patients treat methotrexate , cyclosporin , gold cytotoxic agent control asthma concurrent condition within last 3 month . Patients receive escalate dos immunotherapy , oral immunotherapy short course ( rush ) immunotherapy rhinitis . Patients evidence ( physical exam ) oropharyngeal candidiasis . Exposure investigational drug within 30 day prior screen visit Require continuous treatment beta blocker MAO inhibitor , tricyclic antidepressant , anticholinergic , inhale nedocromil cromolyn , nebulized therapy ( exclude sponsor provide albuterol MDI ) Inability tolerate unwillingness comply require washout period applicable medication Treatment time lifethreatening asthmatic episode ( e.g. , episodes require intubation and/or associate development hypercapnia , hypoxia seizure , etc . ) Patients receive follow treatment meet follow condition within six week prior screen visit : Oral injectable corticosteroid upper respiratory tract infection and/or sinusitis associate exacerbation asthmatic symptom emergency room treatment hospitalization asthmatic symptom . History and/or presence nonasthmatic acute chronic lung disease , include limited bronchitis ( within previous 6 month ) , emphysema , active tuberculosis , bronchiectasis cystic fibrosis . Presence clinicallysignificant cardiovascular disease ( include cardiac arrhythmia uncontrolled hypertension ) , clinicallysignificant hepatic , renal , endocrine dysfunction , stroke , uncontrolled diabetes , hyperthyroidism , convulsive disorder , neoplastic disease basal cell carcinoma , significant psychiatric disease . History glaucoma cataract Presence systemic fungal , bacterial , viral parasitic infection and/or ocular herpes simplex Unlikely compliant , take study medication direct , complete diary card , attend schedule clinic visit require .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>